Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 3/2005

01-06-2005 | Letter

Superior vena cava syndrome: a rare clinical manifestation of Behçet’s disease

Authors: Ismail Hanta, Gamze Ucar, Sedat Kuleci, Süleyman Ozbek, Ali Kocabas

Published in: Clinical Rheumatology | Issue 3/2005

Login to get access

Excerpt

Behçet’s disease is a multisystemic, chronic inflammatory disease of unknown etiology characterized by recurrent episodes [1, 2]. Arterial and venous thrombosis due to Behçet’s disease, although not frequent, can be seen in clinical presentation [3]. The involvement of larger vessels such as the vena cava superior was reported to be less than 2% [4]. …
Literature
1.
Erkan F, Gül A, Tasali E (2001) Pulmonary manifestations of Behçet’s disease. Thorax 56:572–578CrossRefPubMed
2.
Sakane T, Takeno M, Suzuki N (1999) Behçet’s disease. N Engl J Med 21:1284–1291CrossRef
3.
Terzioglu E, Kirmaz C, Uslu R (1998) Superior vena cava syndrome together with multiple venous thrombosis in Behçet’s disease. Clin Rheumatol 17:176–177PubMed
4.
Roguin A, Edelstein S, Edoute Y (1997) Superior vena cava syndrome as a primary manifestation of Behçet’s disease. Angiology 48:365–368PubMed
5.
Gray B, Olin J, Graor R (1991) Safety and efficacy of thrombolytic therapy for superior vena cava syndrome. Chest 99:54–59PubMed
Metadata
Title
Superior vena cava syndrome: a rare clinical manifestation of Behçet’s disease
Authors
Ismail Hanta
Gamze Ucar
Sedat Kuleci
Süleyman Ozbek
Ali Kocabas
Publication date
01-06-2005
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 3/2005
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-004-0958-8

Other articles of this Issue 3/2005

Clinical Rheumatology 3/2005 Go to the issue

Original Article

Serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis and knee osteoarthritis

Letter

Systemic sclerosis following oral contraception

Original Article

Serological screening for celiac disease in premenopausal women with idiopathic osteoporosis

Original Article

Survival of patients with SLE admitted to an intensive care unit—a retrospective study

Case Report

ENT Wegener’s granulomatosis can hide severe central nervous system involvement

Original Article

Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1α(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits